Mistral Continuous (Dienogest, Ethinylestradiol | Lactose)

Mistral Continuous, a combined oral contraceptive, acts within the hormonal contraception pathway to prevent pregnancy and manage menstrual disorders.

• Contraception: prevents pregnancy by suppressing ovulation, thickening cervical mucus and altering the endometrial lining.
• Menstrual cycle regulation: reduces irregular bleeding and stabilizes cycle length for women with dysfunctional uterine bleeding.
• Hormonal acne treatment: may improve acne associated with androgen excess by providing anti‑androgenic progestogen activity.

• Both dienogest and ethinylestradiol bind to steroid receptors to modulate the hypothalamic‑pituitary‑ovarian axis. Ethinylestradiol provides estrogenic activity that stabilizes the endometrium, while dienogest, a progestogen with anti‑androgenic properties, suppresses the luteinizing hormone surge, preventing follicular rupture. The combination also increases cervical mucus viscosity and induces endometrial thinning, creating an environment unfavorable for fertilization and implantation.

Mistral Continuous may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Breast tenderness: discomfort or swelling of the breasts.
• Headache: transient cranial pain.
• Breakthrough bleeding: spotting between periods.
• Weight gain: slight increase in body weight.
• Mood changes: irritability or mood swings.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Arterial thrombosis: stroke or myocardial infarction.
• Hypertension: new or worsening high blood pressure.
• Liver dysfunction: jaundice or abnormal liver enzymes.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Depression: severe mood disorder requiring medical attention.

Before prescribing Mistral Continuous, clinicians should consider several precautionary measures to ensure patient safety.

• Contraindications: known thrombophilia, estrogen‑dependent tumor, active liver disease, pregnancy or breastfeeding.
• Smoking: avoid use in women over 35 who smoke due to increased cardiovascular risk.
• Cardiovascular risk: assess history of hypertension, stroke, or myocardial infarction before initiation.
• Drug interactions: review concomitant medications that may affect hormone levels.
• Monitoring: periodic evaluation of blood pressure and menstrual pattern is recommended.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Mistral Continuous can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin): may markedly reduce contraceptive efficacy.
• Anticoagulants (e.g., warfarin): combined use may increase risk of thrombotic events.
• Selective estrogen receptor modulators: may interfere with hormonal balance.

Moderate Interactions (Monitor Closely)

• Antifungal agents (e.g., ketoconazole, itraconazole): can increase plasma hormone concentrations.
• Herbal supplements (e.g., St John’s wort): may decrease contraceptive effectiveness.
• Certain antibiotics (e.g., tetracycline, metronidazole): potential modest reduction in efficacy; monitor for breakthrough bleeding.